Arpeggi Inc.

Arpeggi Inc. specializes in innovative genetic testing services, crafted for both medical professionals and end consumers, delivering precision in genetic insights for diverse applications. Arpeggi Inc. provides genetic testing solutions, including Whole Genome Sequencing and targeted panels.

The company was acquired by Gene by Gene, Ltd. in August 2013, following a deal finalized on July 13, 2013. The headquarters is located in Austin, US. The recent funding round was a Seed round led by StartUp Health and included participation from GE Ventures, raising a total of USD 200,000.

Arpeggi Inc. offers a wide array of genetic testing services tailored for both practitioners and consumers. Their primary offerings encompass Whole Genome Sequencing (WGS), Next Generation Sequencing (NGS) for custom targeted panels, Microarray technology, and various relationship testing services, including paternity and maternity testing. Utilizing advanced biotechnology and robotic automation, they provide accurate genetic data for precision medicine, variant screening, and inherited disorder identification.

The company caters to a varied clientele, including healthcare professionals, research institutions, and individuals seeking personal genetic insights, mainly operating across North America, Europe, and parts of Asia. Arpeggi Inc. operates on a transactional revenue model, engaging both B2B and direct-to-consumer markets. The company generates revenue through individual service transactions and bundled offerings designed for specific client needs.

Services such as paternity testing and wellness reports are accessible directly to consumers via the firm's platform. Their flagship products, Whole Genome Sequencing and Microarray testing, are positioned as premium services that reflect a commitment to quality and precision in genetic testing. Arpeggi Inc. is focused on expanding its product portfolio and market presence.

Plans include the development of new genetic testing products, though no specific release dates have been mentioned. The company aims to enter new geographic markets beyond its current operations in North America, Europe, and parts of Asia, although targeted regions have not been specified. The recent Seed funding round, which raised USD 200,000, will support these growth initiatives, following the acquisition by Gene by Gene, Ltd. in 2013.